证券代码：300246 证券简称：宝莱特 广东宝莱特医用科技股份有限公司投资者关系活动记录表 编号：20250602 | |  特定对象调研分析师会议 | | --- | --- | | 投资者关系活 | 媒体采访业绩说明会 | | 动类别 | 新闻发布会路演活动 | | |  现场参观 | | | 其他 | | 时间 | 2025 年 6 月 17 日 | | 地点 | 宝莱特公司会议室 | | 参与单位名称 | 善思投资：詹世乾 | | | 世纪财通投资：何工 | | | 钟朝 钟亮 魏军 | | 上市公司接待 | 董事会秘书兼副总裁 杨永兴 | | 人员姓名 | 证券事务代表 李韵妮 | | | 证券事务专员 钟欣昊 | | | 公司介绍环节： | | | 宝莱特成立于 1993 年，主营业务为医疗器械产品的研发、生产、销 | | | 售。公司作为中国最早一批研发制造医疗监护仪的民族企业，是国家发改 | | 投资者关系活 | 委授予的"国家多参数监护仪产业化基地"、工业和信息化部认定的"第八 | | 动主要内容介 | 批国家级制造业单项冠军企业"，目前公司的监护设备已覆盖数千家医疗 | ...

5月28日，宝莱特今日收盘7.31元，下跌1.35%，最新市净率1.64，总市值19.34亿元。 截至2025年一季报，共有3家机构持仓宝莱特，其中其他2家、基金1家，合计持股数623.43万股，持股 市值0.43亿元。 序号股票简称PE(TTM)PE(静)市净率总市值(元)16宝莱特-31.90-27.071.6419.34亿行业平均 48.8147.104.62105.75亿行业中值35.4637.052.4048.69亿1天益医疗-1731.42-2965.731.8522.06亿2澳华内 镜-615.52308.724.9364.87亿3诺唯赞-394.38-466.452.1684.40亿4爱朋医疗-347.79264.224.1928.54亿5博晖 创新-323.49513.323.4547.46亿6硕世生物-134.75-1969.031.2139.41亿7奥精医疗-127.64-187.081.6823.69亿 8睿昂基因-99.17-81.421.4112.84亿9康泰医学-85.71-72.413.0656.41亿10中红医疗-71.83-57.300.9149.92亿 11华大智造-55 ...

Financial Performance - In 2024, the company achieved total revenue of 36.726 billion CNY, a year-on-year increase of 5.14% [2] - The net profit attributable to shareholders was 11.668 billion CNY, up 0.74% year-on-year; excluding financial expenses, the net profit growth was 4.36% [2] - Operating cash flow reached 12.432 billion CNY, reflecting a year-on-year increase of 12.38% [2] - For Q1 2025, total revenue was 8.237 billion CNY, a decline of 12.12% compared to the same period last year, with net profit down 16.81% [9] Dividend Distribution - The company plans to distribute 679 million CNY (including tax) as dividends for 2024, with a cumulative cash dividend of 7.602 billion CNY, representing a payout ratio of 65.15% [3] - A proposal for a mid-year dividend of 1.71 billion CNY (including tax) for 2025 is also in place, pending shareholder approval [3] Market Performance International Market - The international market grew by 21.28% in 2024, with the Asia-Pacific region seeing nearly 40% growth driven by countries like Australia, Thailand, and India [4] - International revenue accounted for approximately 45% of total revenue, with high-potential segments like minimally invasive surgery and cardiovascular care nearing 10% of international income [4] Domestic Market - The domestic market experienced a decline of 5.10% due to sluggish hospital equipment procurement and the impact of DRG 2.0 [4] - A recovery is anticipated in Q3 2025 as local fiscal pressures ease and medical equipment projects are initiated [4] Product Line Performance In Vitro Diagnostics (IVD) - The IVD segment grew by 10.82% in 2024, with international IVD growth exceeding 30% [5] - IVD revenue now constitutes 37.48% of total company revenue, surpassing the life information and support segment [5] Medical Imaging - The medical imaging segment grew by 6.60%, with international growth over 15% [7] - The launch of the high-end Resona A20 ultrasound is expected to enhance market presence [7] Life Information and Support - This segment saw a decline of 11.11%, although international growth was in double digits [8] - The company maintains a leading market share in domestic monitoring and respiratory devices despite challenges [8] Research and Development - R&D investment for 2024 was 4.008 billion CNY, accounting for 10.91% of revenue, while Q1 2025 saw 847 million CNY in R&D, representing 10.28% of revenue [11] - New product launches include advanced systems in life information and support, IVD, and medical imaging [12][13] Sustainability Efforts - The company received an AA rating from MSCI ESG and was included in the S&P Global Sustainable Development Yearbook [14] - Carbon emissions intensity decreased by 11.6% compared to 2021, with ongoing projects contributing to sustainability goals [15] Future Outlook - The company anticipates a significant recovery in domestic revenue starting Q3 2025, driven by the resumption of medical equipment projects [10] - Long-term growth strategies focus on digitalization, internationalization, and enhancing the supply chain to adapt to changing market conditions [24][25]